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SUMMARY 
Background 
Intrahepatic microvascular derangements and microcirculatory dysfunction are key in 
the development of liver cirrhosis and its associated complications. Whilst much has 
been documented relating to cirrhosis and the dysfunction of the microcirculation in 
the liver parenchyma, far less is known about the state of the extrahepatic 
microcirculation and the role this may have in the pathogenesis of multiple organ 
failure in end stage liver cirrhosis.  
Aim 
To provide an update on the role of the microcirculation in the pathophysiology of 
cirrhosis and its associated complications and briefly discuss some of the imaging 
techniques which may be used to directly investigate the microcirculation. 
Methods 
A Medline literature search was conducted using the following search terms: 
‘cirrhosis’, ‘microcirculation’, ‘circulation’, ‘systemic’, ‘inflammation’, ‘peripheral’, 
‘hepatorenal’ and ‘hepatopulmonary’. 
Results 
Significant microvascular alterations exist in patients with cirrhosis and the 
heterogeneous character of these, both among organ systems and within specific 
organs, is demonstrated. Data suggests that the systemic inflammation associated 
with advanced cirrhosis, induces microcirculatory dysregulation and contributes to 
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haemodynamic derangement. The resultant vasoconstriction and hypoperfusion in 
the systemic extrahepatic microvasculature, is likely to be instrumental in the 
pathophysiology of organ failure in decompensated cirrhosis. The mechanistic action 
of vasoactive agents used to correct the circulatory disturbance of advanced 
cirrhosis is poorly understood, however it is likely that they involve the 
microcirculation. 
Conclusion 
Further research into the role of the microcirculation in patients with liver cirrhosis 
using devices such as the sidestream- and incident-dark field imaging 
videomicroscopes, will improve physicians understanding of the pathophysiology of 
cirrhosis, and may provide a platform for real time evaluation of an individual’s 
microcirculatory response to vasoactive mediators, thus guiding their therapy.  
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INTRODUCTION 
Cirrhosis is an increasing cause of morbidity and mortality in developed countries. It 
is now the fifth leading cause of death in the United Kingdom and the thirteenth 
worldwide (1, 2). The progression of cirrhosis is characterised by significant intra- 
and extrahepatic microvascular alterations and dysregulation. A dysfunctional 
microcirculation leads to regions of heterogeneous microvascular flow which causes 
tissue hypoxia. In turn, this creates worsening microcirculatory dysfunction and 
ultimately a downward spiral ensues eventually leading to organ failure and death 
(3). The structural and dynamic changes that occur in the microcirculation of cirrhotic 
patients are widespread.  Within the liver, the hepatic microvasculature 
demonstrates increased intrahepatic resistance, and this results in portal 
hypertension and circulatory dysfunction (4-6). Whilst the systemic haemodynamic 
dysfunction of cirrhosis is well characterised, the extra hepatic microcirculation in 
cirrhosis has been less widely studied. Initial reports have shown heterogeneous 
alterations and microcirculatory dysfunction in extrahepatic vascular beds (7), 
however the extent of microcirculatory abnormalities and the impact this may have in 
the pathogenesis of organ failure in end stage liver cirrhosis is yet to be determined. 
In the intensive care setting, technological advancements in hand held 
videomicroscopes have made feasible the monitoring and quantification of the 
microcirculation at the bedside. Certainly, within the context of the critically ill, 
derangements in the microcirculation are frequently encountered, and a direct 
correlation is seen between the degree of microvascular dysfunction present, and 
the development of multiple organ failure in sepsis (8-10). Given the importance of 
restoring a homogenous microvascular flow in septic patients, a number of recent 
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studies have focused on the effect of pharmacological agents on the 
microvasculature. These studies have shown that despite restoration of systemic 
haemodynamics with vasopressor agents there is often not a parallel improvement in 
the microcirculatory alterations, leading to a loss of systemic and microcirculatory 
coherence. Vasoactive pharmacological agents are also commonly used to treat 
cirrhosis and its associated complications, especially in the context of variceal 
bleeding and renal impairment. Unfortunately however, not all patients respond to 
exogenously administered vasoconstrictors, and certainly the microvascular 
response to these agents is poorly defined.   
This article therefore provides an update on the role of the microcirculation in the 
pathophysiology of cirrhosis and its associated complications. We review the 
literature on the study of the microcirculation in the liver parenchyma and 
extrahepatic regional tissue beds. Furthermore, we describe some of the 
microvasculature imaging techniques enabling real time monitoring of the 
microcirculation in vivo, knowledge of which may advance our comprehension of the 
mechanistic action of therapeutic agents and potentially guide future treatment 
modalities within this field of interest. 
 
THE MICROCIRCULATION 
Anatomy and regulation 
At the tail end of the oxygen cascade, and ultimately regulating tissue blood flow to 
match micro-regional oxygen demand, lies the largest ‘organ’ in the body – the 
microcirculation (11). Anatomically it consists of a network of blood vessels less than 
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100micrometres (μm) in diameter including arterioles, capillaries, post-capillary 
venules, and the blood flowing within these vessels (12).  
The structure (and function) of the microcirculation is highly heterogeneous between 
different organ systems.  Arterioles, arising after the original artery has entered an 
organ and bifurcated up to eight times, continue to subdivide until vessel cross-
sectional diameter is <20μm. Below this size, flow continues through capillaries 
wherein the microvessels’ diameter is only marginally larger than the erythrocytes 
flowing within them in single file (8-10μm). Blood is drained away from capillaries 
through increasingly enlarging post-capillary venules.  
Functionally the microcirculation serves to transport oxygen and nutrients to tissue 
cells, and to remove carbon dioxide and other products of metabolism. Additionally, it 
plays a role in immunological function and temperature regulation, in modulating the 
distribution of fluid between the intravascular and extravascular compartments, and 
in delivering therapeutic agents to target cells (3, 13). 
Capillary blood flow is determined by the hydrostatic driving pressure, 
haemorheology, capillary patency, and arteriolar tone. Regulation of microcirculatory 
vascular tone, ultimately determining capillary patency, can be viewed as a three-tier 
hierarchy; autoregulation (lower tier), intrinsic regulation (middle tier), and extrinsic 
regulation (top tier) (12) (Figure 1). Autoregulation predominantly involves the 
myogenic response to increased blood pressure and distension of the vessel wall. 
Intrinsic regulation involves the release of regulatory molecules to control vessel 
tone; vasodilators of functional hyperaemia (carbon dioxide (CO2), lactate, 
adenosine, Potassium ions), endothelial secretions (nitric oxide (NO), prostacyclin 
(PGI2), endothelin (ET-1), endothelium-derived hyperpolarizing factor (EDHF)) and 
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local paracrine secretions (histamine, serotonin, thromboxane (Tx)). Extrinsic 
regulation allows the central nervous system to exert control of the microcirculation 
through neurohormonal mechanisms. 
 
The hepatic microcirculation is unique due to the dual blood supply of the liver. After 
repeated branching, the hepatic arterioles and portal venules supply blood to the 
hepatic sinusoids. These correspond to the capillary bed of the liver, and are the 
location where transport of nutrients and removal of waste products takes place. The 
hepatic arterioles wind themselves around the portal venules, and it has been 
demonstrated that communication occurs between the vessels. In conditions of 
reduced portal venous flow blood is shunted via hepatic arteriolo-portal anastomoses 
to maintain microvascular perfusion and oxygen delivery (14). Sinusoids run straight 
between the liver cells, and these are lined with specialised endothelial cells 
characterised by flattened processes perforated with small fenestrae, and the 
absence of a basement membrane (15). Hepatic stellate cells (HSC) are located 
external to the endothelium in the space of Disse, a space between the hepatocytes 
and endothelium, and by acting as contractile machinery they play an important role 
in regulating vessel calibre and thus blood flow (16). After passing through the 
sinusoids, blood flows into terminal central veins which combine and reach the 
hepatic vein. 
 
Intrahepatic microcirculation  
In liver cirrhosis, marked changes occur within the intrahepatic microcirculation 
causing disruption to the normal regulatory mechanisms and ultimately leading to an 
increase in intrahepatic vascular resistance and portal hypertension (4-6). The rise in 
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sinusoid resistance is due to both mechanical factors relating to microvascular 
structural changes, and dynamic factors including endothelial dysfunction, reduced 
NO production, increased release of vasoconstrictor products and contraction of 
HSC (17-24). 
Vascular structural changes include angiogenesis and pathological sinusoidal 
remodelling. The sinusoidal endothelial cells (SEC) lose their characteristic 
fenestrations and an organised basement membrane is formed, a process referred 
to as sinusoidal capillarization. This results in an impairment of oxygen diffusion from 
the sinusoidal vessels to the liver parenchyma (25). HSC are also involved in the 
pathological structural changes during sinusoidal remodelling. They migrate and 
promote coverage of sinusoidal vessels leading to vasoconstriction which contributes 
to the high vascular resistance (26). Deposition of collagen in the space of Disse 
leads to narrowing and distorting the sinusoidal lumen, further restricting 
microvascular flow (14). As a result of these changes, the liver tissue becomes 
hypoxic and an accumulation of hypoxia-inducible factors (HIF) stimulates the 
production of angiogenic growth factors such as vascular endothelial growth factor 
(VEGF) (27, 28). The up regulation of VEGF not only leads to angiogenesis, but also 
stimulates activation and migration of HSC which induces an inflammatory response 
and further enhances the process (29-31). Angiogenesis results in new vessel 
formation and shunting between pre-and post-sinusoidal vessels (17). A rise in portal 
vein pressure is seen due to inadequate dilatation of poorly compliant abnormal 
intrahepatic neo-angiogenic vessels (32). The new vessels themselves also further 
perpetuate the inflammatory response by expressing adhesion molecules and 
chemokines promoting the recruitment of inflammatory cells (25). 
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SEC normally release vasoactive substances to maintain sufficient flow. In liver 
cirrhosis, an imbalance occurs leading to impaired vasorelaxation - a process 
referred to intrahepatic endothelial dysfunction (20). NO has been recognised as the 
main endothelial vasodilator of the sinusoidal microcirculation (21). In cirrhosis, NO 
levels in the intrahepatic microcirculation have been shown to be insufficient to 
prevent excessive vasoconstriction and increased hepatic vascular tone (22). The 
reduced bioavailability of NO is the hallmark of endothelial dysfunction and is due to 
decreased endothelial NO synthase (eNOS) activity resulting from oxidative stress, 
regulatory defects and increased level of eNOS inactivators (23 ,33). Although NO 
has been shown to be the primary molecule involved in vasodilation, there are 
number of other endothelial dilators identified to be deficient in cirrhosis and an 
increased release of vasoconstrictive mediators such as TxA2 and ET-1 (23). 
 
Splanchnic microcirculation 
The enhanced intrahepatic resistance leads to a rise in portal pressure and a 
reduction in hepatic perfusion. Maladaptive splanchnic vasodilatation occurs in an 
attempt to restore hepatic perfusion increasing blood inflow with a resultant rise in 
portal pressure. Rather than improving hepatic perfusion, this hyperaemia and portal 
hypertension ultimately leads to the development of a collateral circulation and porto-
systemic shunting. An interesting concept relating to this, was put forth by Newby 
and Hayes in 2002 (34). They proposed that as splanchnic vasodilatation and porto-
systemic shunting increases, progressively more of the cardiac output is diverted into 
the splanchnic circulation at the expense of the extrahepatic vascular beds - a 
splanchnic steal phenomenon. In attempt to correct these circulatory derangements, 
 
 
 10 
homeostatic activation of a cascade of neurohormonal vasoconstrictor systems 
causes extrahepatic peripheral vasoconstriction and reduced tissue perfusion. This 
theory is at odds with the generally accepted view that liver cirrhosis is associated 
with peripheral vasodilatation and a hyperdynamic circulation. Newby and Hayes 
supported their claim with a number of assertions. Firstly, systemic sympathetic 
blockade of the sympathetic nervous system (SNS) or renin angiotensin system 
(RAAS) causes profound hypotension and reduction in systemic vascular resistance, 
for all peripheral sympathetic systems are working at their maximal.  Secondly it 
explains the impaired pressor responses to administered vasoconstrictor agents, 
since the basal vascular tone of the extra-splanchnic circulations is already 
increased and thus cannot be increased anymore. Whilst these notions have yet to 
be substantiated, direct observation of the microcirculation may provide evidence to 
support this theory. Furthermore, sodium and water retention occurs, resulting in an 
expansion of the plasma volume and an increased cardiac output (35). This 
hyperdynamic circulation increases portal venous inflow further, further exacerbating 
portal hypertension and splanchnic steal of blood contributing the development of 
hepatorenal syndrome (HRS) and multiple organ dysfunction (36-40). 
The mechanisms responsible for splanchnic vasodilatation have been extensively 
investigated, and as with the sinusoidal microcirculation, NO is considered to be the 
pivotal factor. NO bioavailability is increased at the level of the splanchnic 
microvasculature in patients with cirrhosis and portal hypertension, mostly because 
of an increased activity of eNOS (41). This upregulation of eNOS is classically 
thought to be triggered by an increase in portal pressure leading to circumferential 
vascular stretch in the splanchnic microcirculation activating the production of VEGF 
and eNOS (42). VEGF promotes angiogenesis and plays an important role in the 
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pathogenesis of the porto-systemic collateral circulation. Interestingly, in the recent 
systemic inflammation hypothesis, Bernadi et al (43) propose that the overproduction 
of eNOS derived NO may precede splanchnic vasodilatation. Thus, the 
hyperdynamic circulation and enhanced mechanical shear force could represent a 
feed forward mechanism further increasing eNOS upregulation. The review suggests 
that pro-inflammatory cytokines, including tumour necrosis factor  (TNF-), 
contribute to NO-mediated vasodilatation.  TNF- induces protein kinase B (also 
known as Akt) mediated eNOS upregulation and anti-TNF- therapies have been 
observed to attenuate the hyperdynamic circulation in portal hypertensive animals 
(44-46). Asides from eNOS and NO upregulation, splanchnic vasodilatation is also 
caused by several other vasoactive mediators including PGI2, carbon monoxide 
(CO), endothelium derived hyperpolarising factors (EHF) and endocannaboids (41). 
 
Extrahepatic microcirculation 
In cirrhosis, the systemic circulation classically undergoes progressive generalized 
vasodilatation (47), although there is an increasing body of evidence refuting this. 
Reduced blood flow has been demonstrated in the peripheral limbs, renal and 
cerebral macrovasculature of patients with liver disease (48-53). In one study, 
McAvoy et al (54) examined differential visceral blood flow in Child Pugh B and C 
cirrhotics. Their findings demonstrating selective regional increases in blood flow in 
the splanchnic and hepatic circulations, yet diminished flow in other regional tissues 
despite the hyperdynamic circulation, support the splanchnic steal concept. 
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Whilst the haemodynamic derangements in the systemic macrocirculation have been 
extensively studied, albeit with contrasting findings, much less is known about the 
state of the extrahepatic systemic microcirculation in cirrhosis. The systemic 
microcirculation and its role in disease pathophysiology is an area of growing 
interest, in part facilitated by the recent development of medical imaging technology 
which allows the microcirculation to be directly visualised in vivo. Within the context 
of critically ill patients, derangements in the microcirculation are frequently 
encountered causing disruption to regulatory mechanisms (8, 55, 56). The resultant 
microcirculatory dysfunction is characterized by heterogeneous abnormalities in 
blood flow and a regional mismatch in oxygen demand and supply (10), and this has 
been associated with worsening clinical outcomes and organ failure (9, 56).  
Multiorgan dysfunction is commonly seen in decompensated cirrhosis, acute-on-
chronic liver failure (ACLF), and in sepsis, and there is increasing evidence that the 
underlying pathophysiological mechanisms may be similar. The systemic 
inflammation hypothesis proposes that decompensation of cirrhosis occurs in the 
setting of severe systemic inflammation and oxidative stress (43). Recent findings 
published by the CANONIC study group (57) strongly support the hypothesis, and 
indicate that systemic inflammation is the cause of decompensation in cirrhosis. The 
main mechanism of inflammation is translocation of bacteria, albeit without overt 
infection, and the spread of pathogen-associated molecular patterns (PAMPs) (58, 
59). PAMPs interact with immune cells and epithelia stimulating intracellular 
signalling pathways, leading to the expression of genes encoding inflammatory 
molecules (43). Evidence from sepsis demonstrates high levels of circulating 
inflammatory mediators, and reactive oxygen species, cause deleterious effects on 
microcirculatory homeostasis, microcirculatory thrombosis, mitochondrial and cell 
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dysfunction, ultimately leading to cell death (60, 61). The picture of advanced 
cirrhosis could therefore be described as a systemic inflammatory multiorgan 
syndrome with associated haemodynamic disturbance, bearing a close resemblance 
to sepsis. 
In view of the vascular abnormalities and systemic inflammation present in cirrhosis, 
it is logical to hypothesise that extrahepatic microvascular alterations exist, and that 
they play a key role in the pathogenesis of multiple organ failure.  Notably, however, 
a dissociation between microvascular perfusion and global haemodynamic variables 
has been well documented (10, 62-64), as has the heterogeneity of the 
microvasculature within different organ systems (10, 65). Accordingly, this makes 
drawing conclusions about various pathophysiological states difficult to achieve, 
though direct visualisation of the microcirculation in vivo can aid this.  
 
i. Peripheral microcirculation 
The sublingual microcirculation was evaluated in cirrhotic patients with and without 
sepsis using sidestream dark field imaging (SDF) by Sheikh et al (7). They found that 
microvascular perfusion was significantly impaired in decompensated cirrhotic 
patients when compared to compensated cirrhotic patients secondary to 
vasoconstriction. Furthermore, they also demonstrated that the sublingual 
microcirculation in patients with decompensated liver cirrhosis had a very similar 
appearance to one with sepsis, lending support to the systemic inflammation 
hypothesis. Activation of inflammation is key in the pathogenesis of microvascular 
alterations in sepsis, and high plasma levels of inflammatory cytokines such as TNF-
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, interleukin (IL)-1, IL-6 and key regulatory cytokines (G-CSF and GM-CSF) 
promoting activation of monocytes and neutrophils, are present in decompensated 
cirrhosis (58, 60, 66, 67). Acute-on-chronic liver failure (ACLF) is a recently 
recognised syndrome, characterised by acute decompensation of cirrhosis, 
multiorgan failure and high short term mortality (68). Within ACLF, cytokines and 
chemokines involved in the innate, rather than adaptive, immune system are 
upregulated. This suggests that a dysregulated immune response leading to 
microcirculatory dysfunction, may be the predominant pathophysiological mechanism 
in the progression from decompensated cirrhosis to organ failure (58). In sepsis, 
there is heterogeneous expression of inducible NO synthase (iNOS) (69), a 
substance found to be elevated in cirrhosis (70) and implicated in the development of 
pulmonary microvascular alterations (71), which is thought to result in pathological 
shunting of blood flow in the microvasculature. Impaired red cell deformability 
leading to enhanced aggregation has been identified in both conditions (72, 73), as 
has increased leucocyte and platelet rolling, and adhesion to the endothelial surface 
possibly impairing circulation of other cells (25, 74).  
A second study utilised SDF imaging to investigate the effect of age, diabetes, 
cirrhosis and chronic kidney disease on sublingual microvascular flow (75). Eighteen 
patients with liver cirrhosis of varying aetiologies were investigated, seventeen with 
Child-Pugh class A and one with Childs-Pugh B. In this instance, the findings differed 
to Sheikh et al in that there was a non-significant trend towards increased 
microcirculatory flow in cirrhotic patients when compared to controls. This may 
represent the lower disease severity of the study participants as early in the course 
of the disease the decrease in systemic vascular resistance may be 
haemodynamically compensated by a rise in cardiac output, prior to the excessive 
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activation of vasoconstrictor systems. Aside from the use of SDF imaging, other 
technologies have been utilised to assess the dynamic response of the peripheral 
microcirculation in liver cirrhosis. Using near infrared spectroscopy (NIRS), Thomson 
et al (76) found that patients with liver cirrhosis had a significantly larger post-
occlusive hyperaemic response than controls indicating microvascular dysfunction.  
Finally, laser Doppler spectroscopy performed on nineteen patients with liver 
cirrhosis, observed reduced flow in the peripheral microcirculation compared to 
controls (77). 
 
ii. Renal microcirculation 
Renal dysfunction is a frequent complication in cirrhosis resulting from inflammation, 
renal hypoperfusion, cardiac and circulatory dysfunction. Excessive splanchnic 
vasodilatation and splanchnic steal of blood causes homeostatic stimulation of the 
RAAS, SNS and antidiuretic hormone leading to renal vasoconstriction. Additionally, 
circulating inflammatory mediators may trigger endothelial dysfunction and 
microcirculatory dysregulation (23, 78). The end result is a marked decrease in renal 
perfusion and glomerular filtration rate (GFR), renal tubular damage, increased 
serum creatinine concentration and ultimately HRS. Vasoconstriction is also likely 
present at the level of the microcirculation, as experimental studies in cirrhotic rats 
have demonstrated heterogeneous alterations in the renal cortical microcirculation 
with reduced vessel diameter and impaired perfusion (79, 80). Toll-like receptor 4 
(TLR4) has been identified as playing an important role in HRS, and it is 
overexpressed in the kidney tissue and urine in cirrhotic patients with acute kidney 
injury (81). TLR4 is activated by PAMPs, upregulating the release of inflammatory 
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mediators which induce endothelial and microcirculatory disruption (82). Endothelial 
dysfunction at a microvascular level is associated with a reduction in renal 
vasodilator production demonstrated by decreased urinary excretion of prostaglandin 
(PG)E2, 6-keto PGF1α (a PGI2 metabolite) and kallikrein (83, 84). This imbalance 
between the activity of systemic vasoconstrictor systems and renal production of 
vasodilators favours vasoconstriction (85). Renal hypoperfusion ensues which is 
further amplified by the stimulation of intrarenal vasoconstrictors including ET-1 and 
angiotensin (86).  
Terlipressin is used in HRS as it has a much greater effect on vascular vasopressin 
receptors (V1) than renal vasopressin receptors (V2), thereby reducing the steal into 
the splanchnic circulation, and diverting blood to the systemic and renal circulations, 
improving renal function in around 50% of patients (87). The ultimate aim of restoring 
renal tissue perfusion is related more to microvascular perfusion than arterial blood 
flow (88), however, the renal microcirculatory response to Terlipressin in HRS is 
poorly defined. Schnieder et al (89) observed the renal microcirculation using 
contrast-enhanced ultrasonography in four HRS patients following Terlipressin 
administration demonstrating heterogeneous renal microvascular responses with 
wide individual variability. A dramatic increase in renal microcirculatory perfusion 
following Terlipressin was observed in two of the study patients, although there was 
a modest decrease in perfusion in the remaining two patients.  
 
iii. Cerebral microcirculation 
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Cerebral haemodynamic derangement is well known in hepatic failure, and it is 
generally accepted that cerebral blood flow decreases in patients with liver cirrhosis 
(90). Hepatic encephalopathy (HE) is a common complication of advanced cirrhosis 
and carries a very poor prognosis (91). Multiple pathophysiological pathways, mostly 
related to ammonia metabolism, are involved in the development of HE. Mounting 
evidence also suggests that abnormal cerebral haemodynamics, and a loss of 
cerebral autoregulation, plays a key role in the pathophysiology (92-95). 
Transcranial Doppler ultrasonography (TCD) can be reliably used to measure 
cerebral blood flow and indices of cerebral vascular resistance (CVR). Macías-
Rodríguez et al (96) measured cerebral vascular resistance using TCD and showed 
CVR is increased in association with the severity of cirrhosis and the presence of 
HE. Kawakami et al (92) found higher CVR in both patients with liver cirrhosis and 
HE, and those with advanced liver disease secondary to other pathologies. Guevara 
et al (97) demonstrated increased resistance of both the renal artery and middle 
cerebral artery in patients with cirrhosis and ascites, and further noted it closely 
correlated with markers of vasoconstrictive systems (RAAS and SNS). These 
findings support the notion that the cerebral vascular bed is affected by tissue 
hypoperfusion and organ dysfunction, in a similar manner to the renal and peripheral 
vascular beds, and adds to the evidence that cerebral haemodynamic derangement 
is involved in the pathophysiology of HE. 
The increase in CVR is likely to be secondary to microvascular dysregulation and 
structural deterioration due to high levels of inflammatory cytokines and neutrophil 
dysfunction, coupled with the associated activation of the RAAS and SNS (96). 
Endothelial disruption and microvascular damage ultimately lead to haemodynamic 
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derangement, and may promote astrocyte oxidative stress, consequently increasing 
the blood brain barrier to ammonia, worsening HE (98). Thus, it is plausible that 
vasopressor agents targeting the cerebral microcirculation could be beneficial in HE, 
as they are in HRS. That said, a study in acute liver failure with severe 
encephalopathy demonstrated worsening of cerebral hyperaemia following the 
administration of terlipressin (99). Cerebral hyperaemia and increased intracranial 
pressure are usually associated with acute liver failure, although interestingly some 
patients with chronic liver disease, who undergo a transjugular intrahepatic 
portosystemic stent (TIPPS) insertion, develop acute cerebral vasodilatation. This 
closely correlates to whole body NO production, and is thought to be driven by an 
iNOS dependent mechanism (100). 
 
iv. Pulmonary microcirculation  
Pulmonary microvascular complications are seen in liver cirrhosis in the form of 
hepatopulmonary syndrome (HPS) and portopulmonary hypertension (POPH). HPS 
is the term used for intrapulmonary microvascular dilatation resulting in impaired 
oxygenation in patients with liver disease and/or portal hypertension (101). Most 
cases occur in advanced cirrhosis although HPS has been recognized in patients 
with adequate hepatic synthetic function (102) and is only manifested in 10-17% of 
the overall cirrhotic population (103, 104), indicating that the pathogenesis of 
microvascular dysfunction in the lung is distinct from the cirrhosis induced systemic 
microvascular alterations. Studies using experimental animal models of cirrhosis 
have identified a number of vasoactive mediators including NO and ET-1. ET-1 is 
classically recognized as a potent vasoconstrictor yet in liver cirrhosis elevated levels 
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of ET-1 cause activation and increased expression of pulmonary ETB receptors 
resulting in NO-mediated vasodilatation via upregulation of pulmonary eNOS (105, 
106). Human studies have observed increased exhaled NO concentrations in 
patients with HPS, which normalise after liver transplantation (107-109). Additionally, 
it has been proposed that lung endotoxaemia is responsible for increased levels of 
TNF- and upregulation of iNOS, further enhancing NO levels (110).  
POPH is best defined as pulmonary arterial hypertension associated with portal 
hypertension, whether or not portal hypertension is secondary to an underlying liver 
disease (111). It is characterised by vasoconstriction and vascular remodelling; 
however, the pathophysiology is poorly understood. A proposed mechanism 
suggests that the high cardiac output seen in the hyperdynamic circulatory syndrome 
causes pulmonary vascular wall shear stress. This then triggers endothelial 
dysfunction with the expression of vasoactive, proliferative and angiogenic mediators 
leading to vascular remodelling (112). An increased expression of vasoconstrictor 
molecules including ET-1 and TxB1 has been implicated in the pathophysiology of 
POPH (113-115), as has serotonin (112). 
 
Monitoring the microcirculation in cirrhosis 
Given the dissimilar, and at times contradictory findings detailed above, it is difficult 
to draw outright conclusions regarding the state of the microcirculation in cirrhotic 
patients. Significant microvascular alterations exist and the heterogeneous character 
of these, both among organ systems and within specific organs, has been 
demonstrated. Vasoconstriction and reduced perfusion predominate in the small 
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number of studies measuring blood flow in the systemic extrahepatic 
microvasculature, and this supports the splanchnic steal hypothesis. Nevertheless, 
the exact nature of these alterations, and the clinical implications of these changes 
remains to be determined, emphasising the need for further investigation and robust 
monitoring of the microcirculation in cirrhosis. 
Recently it has been shown that patients with cirrhosis who recover from bacterial 
infections have a worse prognosis when compared to patients with similar disease 
severity without a history of infection (116). Changes in the microcirculation may be 
responsible for this observation given that microcirculatory alterations have been 
shown to persist even after recovery of systemic haemodynamics in septic shock (9). 
Treatment regimens involving vasoactive agents can be effective in correcting the 
circulatory disturbance of decompensated cirrhosis and hepatorenal syndrome, 
however, a wide variability in patient response is observed, with some demonstrating 
little benefit (87). Whilst our understanding of the mechanistic action of these 
vasoactive agents remains somewhat limited, it is likely that they involve the 
microcirculation. As such, direct monitoring of the microcirculation in vivo could not 
only aid us to better understand the heterogeneous nature of the microcirculation in 
cirrhosis, but also enable us to quantify the effects of therapeutic interventions upon 
it, and evaluate the relationship with clinical outcomes.  
 
Evaluation of the microcirculation 
The intrahepatic microcirculation poses several challenges to accurate 
measurement, including the dual blood supply of the liver, and difficult access to its 
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vessels. Previous methods used to evaluate hepatic perfusion, include the 
radioactive or fluorescent microspheres technique, inert gas clearance technique 
and multiple indicator dilution technique (14). These invasive techniques generally 
involve the introduction of a substance whose concentration is assessed following 
passage through the hepatic microvasculature, thus providing a surrogate measure 
of hepatic perfusion. Varying degrees of accuracy are seen, and their usage has 
been predominantly in experimental animal models or organs following post-mortem 
removal (117-120). 
In more recent times, intravital microscopy has played a pivotal role in microvascular 
and hepatic physiology research. Advances in optical microscopy have enabled 
visualization of individual cells and capillaries in real time as they interact with their 
natural environment. The technique has since been used to analyse biological 
interactions, monitor hepatic disease and develop novel therapeutic approaches 
aimed at altering microvascular pathology in liver disease (121-123). That said, 
despite the technological advances and wide capabilities of intravital microscopy, it 
remains an invasive technique with which one is unable to directly monitor the 
human hepatic or peripheral microcirculation at the bedside. 
Non-invasive techniques applicable to both the intra- and extrahepatic 
microcirculation include laser Doppler flowmetry, NIRS and video microscopy. Laser 
Doppler flowmetry is an established technique for the real time evaluation of 
microvascular red blood cell flow in tissue (124). The measurement of blood flow is 
based on the Doppler principle – frequency shifts in laser light by moving 
erythrocytes. It has been used to determine intra and extrahepatic microcirculatory 
perfusion, and comparison with intravital microscopy revealed significant correlation, 
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demonstrating its reliability in assessment of hepatic microperfusion (77, 125, 126). 
NIRS is able to monitor real time changes in tissue oxygen saturation using the 
principles of light transmission and absorption. It has been extensively validated in 
the measurement of hepatic oxygenation (127, 128). Intraoperatively, NIRS enables 
real time evaluation of perfusion and oxygenation of hepatic tissue (129), and as 
such, it may become valuable tool in liver transplantation and in the assessment of 
ischaemia-reperfusion injury. NIRS is also utilised in conjunction with vascular 
occlusion tests in evaluation of peripheral microcirculatory function (76).  
Video microscopy techniques that allow in vivo visualisation and measurement of the 
microcirculation are arguably the most useful method available today (88). Based 
upon orthogonal polarization spectroscopy (OPS), SDF and, its most recent iteration, 
incident dark field (IDF) imaging, allow real time visualisation of the microvasculature 
at the bedside using non-invasive hand held videomicroscopes (130-132) (Figure 2). 
Using epi-illumination, a light source is applied to the surface of an organ whereupon 
the light diffuses through the tissue and is subsequently reflected back by deeper 
tissue layers making it translucent (134).  Mucosal surfaces covered by a thin 
epithelial layer can also be visualised, the most common area being the easily 
accessible sublingual region. Numerous capillaries and venules traverse the 
sublingual area (135) and it has been used as a surrogate measure for the 
splanchnic blood flow (136-138). Admittedly, whilst the sublingual region may not be 
representative of the state of the microcirculation in other organ systems, the ease of 
access makes for feasible monitoring of the extrahepatic systemic microcirculation at 
the bedside (7, 75). Quantification of SDF/IDF images is standardized, reproducible 
and validated, allowing the functional perfusion of the microcirculation to be reliably 
analysed (139). Direct observation of the sublingual area allows evaluation of the 
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real-time microcirculatory effects of exogenous vasopressor agents, which in the 
future may provide a platform for individual optimization of treatment. This, in 
combination with the observed relationship between sublingual microvascular 
alterations and clinical outcome in critically ill patients (9, 56), makes it a relevant 
and important anatomical region to study in patients with liver cirrhosis.  
 
CONCLUSION 
Liver cirrhosis is associated with systemic inflammation, regional microcirculatory 
alterations and haemodynamic derangements which may be fundamental to the 
pathogenesis of multiple organ dysfunction. Evidence suggests heterogeneous 
microvascular changes are present in extrahepatic vascular beds, and based upon 
previous work in critical illness, these may correlate to poor clinical outcomes.  The 
exact mechanisms of the conventional vasoactive treatments used in the treatment 
of cirrhotic circulatory dysfunction remain to be determined, although it is plausible 
that their effect may be elicited at the level of the microcirculation. Further research 
into the role of the microcirculation in patients with liver cirrhosis using devices such 
as the SDF and IDF videomicroscopes, is therefore essential.  Not only could work in 
this field improve physicians understanding of the pathophysiology of this disease, 
but it may provide a platform for real time evaluation of an individual’s 
microcirculatory response to vasoactive mediators and thus guide their therapy, 
providing individualised approach to treatments.  
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FIGURE LEGENDS 
Figure 1. Regulation of microvascular tone 
 
Figure outlining the intrinsic and extrinsic regulatory mechanisms of microvascular 
tone. EDHF = endothelium-derived hyperpolarizing factor. 
 
Figure 2. Incident dark field sublingual microcirculation image 
Typical image of the sublingual microcirculation in a healthy subject taken using an 
incident dark field videomicroscope. A variety of sizes of blood vessel can be seen, 
as can individual erythrocytes seen as black dots. 
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